Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.
- Sponsor
- QLT Inc.
- Study ID
- NCT00049959
- Phase
- PHASE3
- Status
- Terminated
Conditions
- Basal Cell Carcinoma
- Gorlin Syndrome
- Nevoid Basal Cell Carcinoma Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- verteporfin PDT — DRUG
Study Details
The purpose of the two studies is to determine whether an experimental therapy using a photoactive drug, verteporfin, in combination with direct light exposure of basal cell carcinoma of the skin can safely eliminate these skin tumors.
Key Dates
- Status verified
- Mar 2011
- Primary completion
- Mar 31, 2004
- Completion
- Mar 31, 2004
Study Design
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Related Studies
- Familial Investigations of Childhood Cancer PredispositionRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaPHASE2 · Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
- A Beta-only IL-2 ImmunoTherapY StudyPHASE1/PHASE2 · Recruiting · Medicenna Therapeutics, Inc. · San Diego, California
- Basal Cell Carcinoma Chemoprevention TrialPHASE3 · Not Yet Recruiting · VA Office of Research and Development · Providence, Rhode Island